| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.jenburkt.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 229.93 Cr. | |
| Earnings per share (EPS) | 35.96 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 13.93 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.15 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 214.55 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 2.34 | Calculated using Price: 501.00 |
| Dividend Yield | 1.62 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.46 Cr. | 4,589,378 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where it’s entire operations The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products. The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries. Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Product range of the company includes: Consumer Division:
Pharmaceutical Division:
Awards 2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi. |
||
Company Profile
Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta
Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where it’s entire operations
The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.
The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.
Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.
Product range of the company includes:
Consumer Division:
Pharmaceutical Division:
Awards
2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".
| 1 Day |
|
+1.39% |
| 1 Week |
|
-2.36% |
| 1 Month |
|
+3.67% |
| 3 Month |
|
+13.56% |
| 6 Month |
|
+24.38% |
| 1 Year |
|
+16.50% |
| 2 Year |
|
+16.49% |
| 5 Year |
|
+36.57% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 36.05 | 30.06 | 30.05 | 31.77 | 29.28 | 28.55 | 29.75 | 28.54 | 18.89 | |
| Return on Capital Employed (%) | 48.37 | 40.35 | 40.94 | 42.35 | 40.17 | 39.26 | 41.99 | 36.90 | 25.73 | |
| Return on Assets (%) | 15.74 | 13.92 | 16.15 | 18.40 | 18.13 | 20.10 | 22.36 | 21.99 | 14.37 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 19 | 23 | 27 | 33 | 40 | 54 | 61 | 77 | 80 | |
| Non Curr. Liab. | 8 | 9 | 4 | 3 | 4 | 4 | 3 | 0 | 0 | |
| Curr. Liab. | 14 | 18 | 13 | 24 | 14 | 18 | 13 | 25 | 24 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 40 | 49 | 44 | 61 | 58 | 76 | 78 | 103 | 104 | |
| Non Curr. Assets | 14 | 15 | 14 | 12 | 13 | 13 | 12 | 13 | 15 | |
| Curr. Assets | 26 | 34 | 30 | 49 | 45 | 64 | 66 | 90 | 90 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 40 | 49 | 44 | 61 | 58 | 76 | 78 | 103 | 104 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 60 | 69 | 76 | 85 | 94 | 103 | 115 | 123 | 119 | |
| Other Income | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | |
| Total Income | 61 | 70 | 78 | 87 | 96 | 106 | 118 | 126 | 123 | |
| Total Expenditure | -50 | -59 | -65 | -70 | -77 | -84 | -91 | -98 | -99 | |
| PBIDT | 10 | 11 | 13 | 17 | 19 | 23 | 27 | 28 | 24 | |
| Interest | -1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | |
| Depreciation | -1 | -1 | -2 | -3 | -2 | -2 | -2 | -1 | -2 | |
| Taxation | -3 | -3 | -3 | -5 | -6 | -7 | -8 | -7 | -6 | |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | |||||
| PAT | 6 | 6 | 8 | 10 | 11 | 14 | 17 | 20 | 15 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 7 | 5 | 11 | 9 | 8 | 10 | 16 | 13 | 15 | |
| Cash Fr. Inv. | -3 | -1 | 0 | 1 | 0 | -10 | 1 | -11 | -3 | |
| Cash Fr. Finan. | -2 | 0 | -7 | 1 | -5 | 1 | -18 | -2 | -11 | |
| Net Change | 2 | 3 | 5 | 11 | 2 | 1 | -1 | 0 | 1 | |
| Cash & Cash Eqvt | 8 | 11 | 17 | 28 | 30 | 2 | 1 | 1 | 3 |
|
Mon, 26 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate intimation of loss of share certificates as received by a shareholder of the Company. |
|
Mon, 12 Jul 2021
Fixation Of Book Closure And Cur-Off Dates Intimation for the closure of the Members register and share transfer books of the Company for the 36th AGM and dividend along with the cut off date for the eligibility of shareholders for e-voting.in relation to the AGM. |
|
Thu, 08 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance certificate under Regulation 74(5) of SEBI(DP) Regulations 2018 for the quarter ended on 30.06.2021 |
| Fri, 30 Jul 2021 |
Decreasing Relative Strength - Benchmark index
|
Decreasing Relative Strength - Sectoral index
|
Close Within 2 Year High Zone
|
Both SRS And ARS Above Zero
|
5 EMA Crossing 20 EMA From Below
|
Equities
M.F.
Sectors